Press Releases 2019

Below you can access the latest press releases for 2019. Please note that some documents may refer to Liminal BioSciences' previous name Prometic Life Sciences Inc.

  • Liminal BioSciences announces key appointment to its leadership team

    Liminal BioSciences announces key appointment to its leadership team

    LMNL announced today the addition of Moira Daniels as the new Head of Regulatory Affairs and Quality Assurance, to its senior leadership team.

    Read Article
  • Liminal BioSciences presents new preclinical data on PBI-4050 and NASH candidate PBI-4547

    Liminal BioSciences presents new preclinical data on PBI-4050 and NASH candidate PBI-4547

    Read Article
  • Liminal BioSciences reports its 2019 third quarter financial results and business highlights

    Liminal BioSciences reports its 2019 third quarter financial results and business highlights

    Read Article
  • Liminal BioSciences to report Q3 2019 results and hold conference call

    Liminal BioSciences to report Q3 2019 results and hold conference call

    Read Article
  • Liminal BioSciences presents new preclinical data at ASN kidney week 2019

    Liminal BioSciences presents new preclinical data at ASN kidney week 2019

    LMNL collaborators presented new preclinical findings on a novel therapeutic approach to the treatment of inflammatory and fibrosis-related kidney diseases at the American Society of Nephrology’s

    Read Article
  • Liminal BioSciences to divest bioseparations division to KKR

    Liminal BioSciences to divest bioseparations division to KKR

    LMNL announced today the signature of a binding share purchase agreement for the divestment of its Isle of Man-based bioseparations business operated through its subsidiary Prometic Bioseparations Ltd

    Read Article
  • Liminal BioSciences announces upcoming presentations with new data on Pulmonary Arterial Hypertension at the 2019 AHA meeting

    Liminal BioSciences announces upcoming presentations with new data on Pulmonary Arterial Hypertension at the 2019 AHA meeting

    Liminal BioSciences announces upcoming presentations new data on Pulmonary Arterial Hypertension at the 2019 AHA meeting

    Read Article
  • Liminal BioSciences announces upcoming presentations at The Liver Meeting 2019

    Liminal BioSciences announces upcoming presentations at The Liver Meeting 2019

    Liminal Bio anannounced the presentation of three abstracts related to the Company’s pre-clinical development activities for the treatment of liver diseases at the The Liver Meeting 2019 of the AASLD

    Read Article
  • Liminal BioSciences announces upcoming presentations at ASN kidney week 2019

    Liminal BioSciences announces upcoming presentations at ASN kidney week 2019

    Liminal BioSciences and its’ collaborators will present preclinical findings on a novel therapeutic approach to the treatment of inflammatory and fibrosis-related kidney diseases at ASN Kidney Week.

    Read Article
  • Liminal BioSciences to present at H.C. Wainwright & Co. 3rd annual NASH investor conference

    Liminal BioSciences to present at H.C. Wainwright & Co. 3rd annual NASH investor conference

    Liminal BioSciences announced today, that members of the management team will provide a presentation on PBI-4547 as a potential treatment for NASH

    Read Article
  • Prometic shareholders approve name change to Liminal BioSciences Inc.

    Prometic shareholders approve name change to Liminal BioSciences Inc.

    Shareholders representing approximatively 87% of votes cast approved a special resolution authorizing the Company to amend its articles to change its name to Liminal BioSciences Inc.

    Read Article
  • Prometic reports first subject dosed in phase I clinical study with single ascending doses of PBI-4547

    Prometic reports first subject dosed in phase I clinical study with single ascending doses of PBI-4547

    PBI-4547 is a novel, orally active immune-metabolic agent which displays antidiabetic, antihyperlipidemic, anti-inflammatory and anti-fibrotic activity as shown in multiple animal models.

    Read Article
  • Prometic Life Sciences to present at H.C. Wainwright & Co. 21st Annual Global Investment Conference

    Prometic Life Sciences to present at H.C. Wainwright & Co. 21st Annual Global Investment Conference

    Members of the management team will provide a business overview and update at the H.C. Wainwright & Co. 21st Annual Global Investment Conference at 11:15 EDT on Tuesday, September 10, 2019 in New York

    Read Article
  • Prometic Life Sciences Announces Intention to change name to Liminal BioSciences Inc.

    Prometic Life Sciences Announces Intention to change name to Liminal BioSciences Inc.

    Prometic announced today its intention to change its name as part of a global rebrand in support of its new vision and values.

    Read Article
  • Prometic reports financial results for second quarter 2019

    Prometic reports financial results for second quarter 2019

    Prometic today announced financial results for its fiscal 2019 second quarter ended June 30th 2019.

    Read Article
  • Correction of previous press release: Prometic to report its second quarter financial results and hold conference call

    Correction of previous press release: Prometic to report its second quarter financial results and hold conference call

    Prometic’s conference call will be held at 8:30 a.m. (EDT), rather than 11:00 a.m. (EDT) on Tuesday, August 13th, 2019.

    Read Article
  • Prometic to report its second quarter financial results and hold conference call

    Prometic to report its second quarter financial results and hold conference call

    Prometic will report its financial results for the second quarter ended June 30th, 2019 on Monday August 12th, 2019 after market close.

    Read Article
  • Prometic Life Sciences to present at Canaccord 39th Annual Growth Conference

    Prometic Life Sciences to present at Canaccord 39th Annual Growth Conference

    Prometic will provide a business overview and update at the Canaccord 39th Annual Growth Conference at 16:30 ET on Wednesday, August 7, 2019 in Boston, USA.

    Read Article
  • Prometic announces share consolidation

    Prometic announces share consolidation

    Prometic is pleased to announce that the consolidation of the Corporation’s issued and outstanding common shares on the basis of one post-consolidation Common Share for every one thousand

    Read Article
  • Prometic announces voting results of its 2019 AGM

    Prometic announces voting results of its 2019 AGM

    Prometic announced the voting results from its 2019 Annual General and Special Meeting of Shareholders (“AGM”) held in Montreal, Quebec

    Read Article
  • loading
    Loading More...